ClinicalTrials.gg
RecruitingNCT05416775Updated Aug 19, 2022

Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

A Phase 1/2 interventional study of SHR-8068;Adebrelimab and SHR-8068;adebrelimab and platinum-based chemotherapy in Advanced Non-small Cell Lung Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 18 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-19.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. — 18 open to participants now, 22 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
24th of 38
168 · median 274
Started
2022
with 2 others
Phase 1/2
7 of 38
5 open now
Primary completion
2026-06
later than 6 of 21 live
Registered
20th of 38
by date

Among the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., this one is the 24th largest by planned enrollment, is one of 3 that started in 2022, is one of 7 in phase 1/2, reaches primary completion later than 6 of the 21 other live ones, and was the 20th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

To evaluate the tolerability and safety of SHR-8068 in combination with adebrelimab in subjects with advanced NSCLC To evaluate the efficacy of SHR-8068 in combination with adebrelimab and platinum-based chemotherapy in subjects with advanced NSCLC

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18\~75 years old, both male and female
  2. Stage 1: diagnosed, incurable NSCLC subjects who have failed standard treatment
  3. Stage 2: have a histologically or cytologically confirmed diagnosis of or NSCLC; have not received prior systemic treatment for their recurrent or metastatic NSCLC; TPS \<50% as confirmed by central laboratory
  4. At least one based on v1.1 criteria
  5. PS score: 0-1 points
  6. Expected survival period ≥ 3 months
  7. Good levels of organ function
  8. Patients voluntarily joined the study and signed

Exclusion criteria

Exclusion Criteria:

  1. Patients with EGFR activating mutation, positive ALK fusion gene or known ROS1 fusion gene
  2. Untreated ; or associated with meningeal , spinal cord compression, etc.
  3. Uncontrolled pleural, pericardial, or ascites with clinical symptoms
  4. Severe bone damage caused by tumor bone metastasis
  5. Suffering from other malignant tumors in the past 3 years or at the same time
  6. Presence of any active or known disease
  7. Systemic treatment with or other within 2 weeks before the first dose
  8. Have clinical symptoms or diseases of the heart that are not well controlled
  9. Serious infection occurred within 1 month before the first dose
  10. Past or current active interstitial lung disease requiring treatment, non-infectious pneumonia requiring glucocorticoid system treatment; current active pneumonia or pulmonary function test confirmed severe impairment of pulmonary function
  11. With active pulmonary tuberculosis
  12. Known positive history of test or acquired immunodeficiency syndrome, known active viral hepatitis
  13. Known history of inflammatory bowel disease
  14. Inoculated with within 28 days before the first dose
  15. Known allergic reaction to other monoclonal antibodies
  16. Received >30 Gy of pulmonary radiotherapy within 6 months before the first dose; received major surgical treatment, systemic chemotherapy, immunotherapy or other clinical trial drugs within 4 weeks before the first dose; within 2 weeks before the first dose Received palliative radiotherapy; oral molecularly targeted drugs, discontinued to less than 5 half-lives before first dose; failure to recover from toxicity and/or complications of previous interventions to NCI-CTC AE ≤1 degree
  17. According to the judgment of the researcher, there are other factors that may affect the results of the study or cause the study to be terminated halfway.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    SHR-8068 in combination with adebrelimab

    Drug: SHR-8068;Adebrelimab

  • Experimental
    SHR-8068 in combination with adebrelimab and platinum-based chemotherapy

    Drug: SHR-8068;adebrelimab and platinum-based chemotherapy

  • Experimental
    Adebrelimab in combination with platinum-based chemotherapy

    Drug: Adebrelimab;platinum-based chemotherapy

Interventions

  • DrugSHR-8068;Adebrelimab

    SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion

  • DrugSHR-8068;adebrelimab and platinum-based chemotherapy

    SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip

  • DrugAdebrelimab;platinum-based chemotherapy

    Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity

    Time frame: The observation period is 21 days after the first dose

  2. Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (complete or partial response) across all assessment time points;

    Time frame: up to 2 years

Secondary outcomes

  1. Disease Control Rate, determined using RECIST v1.1 criteria

    Time frame: up to 2 years

  2. Progression-Free-Survival assessed by investigator

    Time frame: up to 2 years

07

Study locations

1 of 18 sites recruiting
  • Anhui Chest Hospital
    Hefei, Anhui 230000, China
    Not yet recruiting
    • Haohui Fang · Principal investigator
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
    Not yet recruiting
    • Xinghua Han · Principal investigator
  • West China Hospital Of Sichuan University
    Chengdu, Chengdu 610000, China
    Not yet recruiting
    • Yan Zhang · Principal investigator
  • Cancer Hospital Affiliated to Chongqing University
    Chongqing, Chongqing 400030, China
    Not yet recruiting
    • Yongsheng Li · Principal investigator
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi Zhuang Autonomous Region 530022, China
    Not yet recruiting
    • Zhiyi He · Principal investigator
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou 550002, China
    Not yet recruiting
    • Yu Zhang · Principal investigator
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563003, China
    Not yet recruiting
    • Liang Zhou · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Not yet recruiting
    • Yan Wang · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
    Not yet recruiting
    • Yanqiu Zhao · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Not yet recruiting
    • Gunjun Zhang · Principal investigator
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441000, China
    Not yet recruiting
    • Tienan Yi · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410000, China
    Not yet recruiting
    • Yongzhong Luo · Principal investigator
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Jifeng Feng · Principal investigator
  • Affiliated Hospital of Jiangnan University
    Wuxi, Jiangsu 214000, China
    Not yet recruiting
    • Yong Mao · Principal investigator
  • North Jiangsu People's Hospital
    Yangzhou, Jiangsu 225001, China
    Not yet recruiting
    • Lingfeng Min · Principal investigator
  • Jilin Cancer Hospital
    Changchun, Jilin 130103, China
    Not yet recruiting
    • Ying Cheng · Principal investigator
  • Affiliated Tumor Hospital of Shandong First Medical University
    Jinan, Shandong 250000, China
    Not yet recruiting
    • Baosheng Li · Principal investigator
  • Yunnan Cancer Hospital
    Kunming, Yunan 650106, China
    Not yet recruiting
    • Runxiang Yang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Jun 2026, 46 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 46 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 13, 2022
StartActual
Aug 15, 2022
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Aug 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05416775
Responsible party
Sponsor
First posted
Jun 13, 2022
Start date
Aug 15, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Aug 19, 2022

Study contacts

Xin Xu
Contact
xin.xu@hengrui.com
0518-82342973
Weixia Li
Contact
weixia.li@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion